#pharmaceuticals

Amgen says longtime executive David Reese, who currently serves as chief technology officer, will retire at the end of June, marking a leadership change inside one of biotech’s largest companies.

Amneal Pharmaceuticals has agreed to acquire a biosimilar maker for $375 million upfront, highlighting how manufacturers are still using targeted deals to widen portfolios and strengthen their position in harder-to-proc

Anthropic’s appointment of Novartis CEO Vas Narasimhan to its board points to a closer alignment between frontier AI development and the pharmaceutical industry.

A newly approved daily weight-loss pill moved through U.S. FDA review faster than most drugs in recent years, signaling continued momentum in the obesity treatment market.

Eli Lilly and Insilico Medicine have signed a deal worth up to $2.75 billion, deepening a partnership aimed at moving AI-developed drug candidates toward the global market.

After years of development challenges, oral GLP-1 weight loss drugs are finally hitting the market. Novo Nordisk's oral Wegovy is already available, with Eli Lilly's orforglipron expected to win FDA approval soon.

Vinay Prasad, a controversial figure at the FDA's biologics center and key ally of Commissioner Makary, is leaving the agency.

Pfizer has won approval for a GLP-1 obesity drug in China shortly after licensing the shot from Hangzhou-based Sciwind Biosciences.